Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Lab Animal|June 24, 2008
A cost-effective and efficacious method of pinworm treatment for large colonies of miceDebra Hickman, Melissa Swan, G Paul Hartman
Applied Clinical Informatics|August 22, 2024
Coverage of Physical Therapy Assessments in the Observational Medical Outcomes Partnership Common Data ModelMargaret A French, Paul Hartman, Heather A Hayes, et al.
Health Care for Women International|November 7, 2002
The Ohio Midlife Women's StudyGreer Glazer, Richard Zeller, Ladonna Delumba, et al.
Substance Use & Addiction Journal|November 12, 2024
Practice Changes 6 Months Following a Physical Therapist Training Program Regarding Opioid Use and Misuse Screening and Assessment: A Qualitative StudyJohn Magel, Elizabeth Siantz, Priscilla Blosser, et al.
Leukemia & Lymphoma|October 6, 2007
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemiaPaul Barr, Pingfu Fu, Hillard Lazarus, et al.
Substance Abuse|May 25, 2023
Patients' Perceptions of Physical Therapists Addressing Opioid MisuseJohn Magel, Paul Hartman, Julie M Fritz, et al.
Physical Therapy|February 28, 2026
Primary Care Provider Attitudes Regarding Physical Therapists Addressing Opioid Use and Opioid Misuse: A Qualitative StudyJohn S Magel, Elizabeth Siantz, Michael A Incze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignanciesAfshin Dowlati, Hillard M Lazarus, Paul Hartman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.
Pageof 2